By defining a mesothelin-associated anti-senescence (MAAS) effect, our findings reveal a previously unrecognized mechanism of tumor progression and suggest that targeting MSLN could restore senescence, providing a new avenue for therapeutic intervention in PDAC. Here, MSLN is linked to neoplasm.